Simply Statistics A statistics blog by Rafa Irizarry, Roger Peng, and Jeff Leek

New U.S. Research Will Aim at Flood of Digital Data

30 Mar 2012

New U.S. Research Will Aim at Flood of Digital Data

Big Data Meeting at AAAS

29 Mar 2012

The White House Office of Science and Technology Policy is hosting a meeting that will discuss several new federal efforts relating to big data. The meeting is is today from 2-3:45pm and there will be live webcast.

Participants include

  • John Holdren, Assistant to the President and Director, White House Office of Science and Technology Policy
  • Subra Suresh, Director, National Science Foundation
  • Francis Collins, Director, National Institutes of Health
  • Marcia McNutt, Director, United States Geological Survey
  • William Brinkman, Director, Department of Energy Office of Science
  • Zach Lemnios, Assistant Secretary of Defense for Research & Engineering, Department of Defense
  • Kaigham “Ken” Gabriel, Deputy Director, Defense Advanced Research Projects Agency
  • Daphne Koller, Stanford University (machine learning and applications in biology and education)
  • James Manyika, McKinsey & Company (Co-author of major McKinsey report on Big Data)
  • Lucila Ohno-Machado, UC San Diego (NIH’s “Integrating Data for Analysis, Anonymization, and Sharing” initiative)
  • Alex Szalay, Johns Hopkins University (Big Data for astronomy)
Update: Some more information from the White House itself.

Roche Raises Illumina Bid to $51, Seeking Faster Deal

29 Mar 2012

Roche Raises Illumina Bid to $51, Seeking Faster Deal

Justices Send Back Gene Case

27 Mar 2012

Justices Send Back Gene Case

Supreme court vacates ruling on BRCA gene patent!

26 Mar 2012

As Reeves alluded to in his post about the Mayo personalized medicine case, the Supreme Court just vacated the lower court’s ruling in Association for Molecular Pathology v. Myriad Genetics (No. 11-725). The case has been sent back down to the Federal Circuit for reconsideration in light of the Court’s decision in Mayo.  This means that the Supreme Court thought the two cases were sufficiently similar that the lower courts should take another look using the new direction from Mayo.

 It’s looking more and more like the Supreme Court is strongly opposed to personalized medicine patents.